R&D News | pharmaphorum

News

Gilead drops CD47 drug magrolimab for blood cancers

Gilead Sciences has said it will no longer develop its CD47-targeting antibody magrolimab in blood cancers after data suggested that patients taking the drug in clinical t

News

Jazz buys KRAS inhibitors from Redx in $880m deal

Jazz Pharmaceuticals has agreed another pipeline-building deal, this time paying $10 million upfront for rights to a KRAS inhibitor programme from UK biotech Redx Pharma,

News

GSK backs up its Blenrep rehab bid with survival data

GSK has revealed the data it hopes will allow a return to the US market for Blenrep, which was the first BCMA-targeting drug to launch there, but was withdrawn from sale after it fail

News

More pharma M&A as Novartis snaps up MorphoSys for $2.9bn

Novartis is continuing a streak of pipeline-building deals with an agreement to buy Germany’s MorphoSys in a transaction that values the cancer-focused biotech at €2.7 billion (around

News

Vertex’s chief executive Reshma Kewalramani

Vertex seeks swift review of new CF triple after ph3 readout

Vertex Pharma has said it will use a priority review voucher (PRV) to speed up the FDA review of its new once-daily triple therapy for cystic fibrosis, which has just hit

News

Metagenomi prices IPO and NeOnc joins list of hopefuls

Gene editing start-up Metagenomi and cancer specialist NeOnc Technologies have announced the terms of their initial public offerings, in another sign that investor interes

Gilead drops CD47 drug magrolimab for blood cancers

Jazz buys KRAS inhibitors from Redx in $880m deal

GSK backs up its Blenrep rehab bid with survival data

More pharma M&A as Novartis snaps up MorphoSys for $2.9bn

Vertex seeks swift review of new CF triple after ph3 readout

Metagenomi prices IPO and NeOnc joins list of hopefuls

NHS study will pick apart mental illness with data science

How to meet your physicians where they are online

News

Editor's Picks